SK287940B6 - Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use - Google Patents

Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use Download PDF

Info

Publication number
SK287940B6
SK287940B6 SK1774-2002A SK17742002A SK287940B6 SK 287940 B6 SK287940 B6 SK 287940B6 SK 17742002 A SK17742002 A SK 17742002A SK 287940 B6 SK287940 B6 SK 287940B6
Authority
SK
Slovakia
Prior art keywords
ctla4
molecule
soluble
ctla4ig
ser
Prior art date
Application number
SK1774-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK17742002A3 (sk
Inventor
Robert Cohen
Suzette Carr
David Hagerty
Robert J. Peach
Jean-Claude Becker
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22804919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287940(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK17742002A3 publication Critical patent/SK17742002A3/sk
Publication of SK287940B6 publication Critical patent/SK287940B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
SK1774-2002A 2000-07-03 2001-07-02 Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use SK287940B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21591300P 2000-07-03 2000-07-03
PCT/US2001/021204 WO2002002638A2 (fr) 2000-07-03 2001-07-02 Methodes de traitement de maladies rhumatismales a l'aide d'une molecule ctla4 soluble

Publications (2)

Publication Number Publication Date
SK17742002A3 SK17742002A3 (sk) 2004-11-03
SK287940B6 true SK287940B6 (sk) 2012-05-03

Family

ID=22804919

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1774-2002A SK287940B6 (sk) 2000-07-03 2001-07-02 Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use

Country Status (39)

Country Link
US (1) US7455835B2 (fr)
EP (4) EP3384924A1 (fr)
JP (1) JP2004517806A (fr)
KR (3) KR100895552B1 (fr)
CN (1) CN1318086C (fr)
AR (2) AR035037A1 (fr)
AT (1) ATE401909T1 (fr)
AU (2) AU2001273174B2 (fr)
BG (2) BG66024B1 (fr)
BR (1) BR0112104A (fr)
CA (2) CA2630062C (fr)
CY (3) CY1109786T1 (fr)
CZ (1) CZ303959B6 (fr)
DE (1) DE60135029D1 (fr)
DK (2) DK1372696T3 (fr)
EE (1) EE05378B1 (fr)
ES (2) ES2667203T3 (fr)
HK (1) HK1058486A1 (fr)
HR (1) HRP20030071B1 (fr)
HU (3) HU226847B1 (fr)
IL (2) IL153593A0 (fr)
IS (1) IS2834B (fr)
LT (2) LT1935427T (fr)
LV (1) LV12993B (fr)
MX (1) MXPA02012603A (fr)
MY (1) MY137552A (fr)
NO (3) NO20026264L (fr)
PE (1) PE20020772A1 (fr)
PL (2) PL212205B1 (fr)
PT (2) PT1935427T (fr)
RS (1) RS50811B (fr)
RU (1) RU2287340C2 (fr)
SI (3) SI21078A (fr)
SK (1) SK287940B6 (fr)
TR (1) TR201807700T4 (fr)
TW (2) TWI311564B (fr)
UY (1) UY26815A1 (fr)
WO (1) WO2002002638A2 (fr)
ZA (1) ZA200210058B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1536234B1 (fr) * 2000-05-26 2016-03-16 Bristol-Myers Squibb Company Molecules ctla4 mutantes solubles et leurs utilisations
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ES2667203T3 (es) 2000-07-03 2018-05-10 Bristol-Myers Squibb Company Usos de moléculas mutantes de CTL4 solubles
EP1368059A1 (fr) * 2001-01-26 2003-12-10 Emory University Procedes pour induire la tolerance de transplantations d'organe et corriger les hemoglobinopathies
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
EP1496931A4 (fr) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co Methodes de traitement d'une maladie auto-immune au moyen d'une molecule ctla4 soluble et d'un armm ou d'un ains
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
CA2762015A1 (fr) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methodes de traitement d'une maladie cardiovasculaire a l'aide d'une molecule ctla4 soluble
WO2005044188A2 (fr) 2003-10-27 2005-05-19 Amgen Inc. Compositions et procedes de modulation de la reaction immunitaire a un agent therapeutique immunogene
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
ES2436616T5 (es) * 2005-12-20 2022-05-27 Bristol Myers Squibb Co Formulaciones proteicas estables
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PE20080556A1 (es) 2005-12-20 2008-06-13 Bristol Myers Squibb Co Composicion que comprende una poblacion aislada de moleculas ctla4-ig a partir de un medio de cultivo liquido y metodos para su obtencion
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2385065A1 (fr) * 2007-11-01 2011-11-09 Perseid Therapeutics LLC Polypeptides immunosuppresseurs et acides nucléiques
AU2014250683B2 (en) * 2007-11-01 2015-11-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) * 2007-11-01 2014-08-28 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (fr) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Dispositif de mesure de la concentration d'un soluté et procédés associés
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
WO2010049935A1 (fr) * 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Lymphocytes t à mémoire centrale anti-tiers, procédés de production de ceux-ci et utilisation de ceux-ci dans une greffe et un traitement de maladie
EP2932994B1 (fr) 2009-07-30 2017-11-08 Tandem Diabetes Care, Inc. Nouveau joint torique, mécanisme de distribution et système de pompe de perfusion portable qui lui sont associés
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
ES2826894T3 (es) * 2010-02-19 2021-05-19 Xencor Inc Nuevas inmunoadhesinas CTLA4-IG
EP2545073B1 (fr) * 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Protéines ctla4 et leurs utilisations
WO2011146395A2 (fr) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prévention de rejet immunologique de cellules souches transplantées par blocage de molécule costimulante de leucocyte
PL2613801T3 (pl) 2010-09-08 2016-12-30 Zastosowanie komórek T pamięci centralnych przeciwko obcym antygenom do leczenia białaczki/chłoniaka
SG188471A1 (en) 2010-09-08 2013-04-30 Yeda Res & Dev An immunosuppressive drug combination for a stable and long term engraftment
WO2013010537A1 (fr) * 2011-07-20 2013-01-24 Aarhus Universitet Procédé de traitement de la morphée
US20140212398A1 (en) 2011-09-08 2014-07-31 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014151230A2 (fr) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Méthode de traitement d'une granulomatose avec polyangéite
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
WO2016168771A2 (fr) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à affinités accordables
ES2963038T3 (es) 2015-07-16 2024-03-25 Yeda Res & Dev Uso de células T de memoria central antitercero
EP3192805A1 (fr) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibiteurs de l'activation ou la stimulation des lymphocytes t et leurs utilisations
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
EP3571295A1 (fr) 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Cellules veto génétiquement modifiées et leur utilisation en immunothérapie
KR20230020022A (ko) 2017-10-10 2023-02-09 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
US12098179B2 (en) 2018-03-16 2024-09-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765064A1 (fr) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides antigéniques dérivés de pcsk2 et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
WO2019175380A2 (fr) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
KR20210121077A (ko) 2019-01-15 2021-10-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
WO2023112992A1 (fr) * 2021-12-16 2023-06-22 レグセル株式会社 Composition pharmaceutique pour le traitement de maladies, de troubles ou de symptômes liés à une anomalie dans le système immunitaire

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644792A (en) * 1899-09-14 1900-03-06 Stanhope Boal Heater.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
DE69333580D1 (de) 1992-04-07 2004-09-09 Univ Michigan Immunregulation über die cd28-route
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
EP1553168A3 (fr) 1993-06-04 2011-04-06 The United States of America as represented by The Secretary of The Navy Procédé pour la stimulation sélective de la prolifération des cellules T
WO1994028912A1 (fr) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Immunosuppression recourant a la voie d'acces du cd28
CN100341896C (zh) 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
RU2141318C1 (ru) * 1993-12-01 1999-11-20 Санкио Компани Лимитед Ингибитор образования воспалительного цитокина, средство для профилактики и лечения воспалительных заболеваний пищеварительного тракта и синдрома бехчета, способ профилактики и лечения воспалительных заболеваний и язвенного колита
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
CA2191586A1 (fr) 1994-06-03 1995-12-14 Carl H. June Procedes de stimulation selective de la proliferation des cellules t
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US5634055A (en) * 1994-09-27 1997-05-27 Bidplus, Inc. Method for selecting assignments
WO1996014865A1 (fr) 1994-11-10 1996-05-23 Repligen Corporation Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
CA2291338A1 (fr) 1997-06-11 1998-12-17 Wisconsin Alumni Research Foundation Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t
EP0947524A1 (fr) * 1998-03-30 1999-10-06 Upither B.V. Nouveaux peptides destinés au traitement de maladies auto-immunes
ES2205792T3 (es) * 1998-04-03 2004-05-01 Osiris Therapeutics, Inc. Celulas madre mesenquimatosas como inmunosupresores.
CA2333726A1 (fr) * 1998-06-05 1999-12-09 Supergen, Inc. Compositions comprenant methotrexate et pentostatine pour traiter la polyarthrite rhumatoide
JP2000086519A (ja) * 1998-09-17 2000-03-28 Mitsui Chemicals Inc 抗リウマチ薬効果増強剤
IL126681A0 (en) 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
WO2001090122A2 (fr) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes du gene ctla4
EP1536234B1 (fr) * 2000-05-26 2016-03-16 Bristol-Myers Squibb Company Molecules ctla4 mutantes solubles et leurs utilisations
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ES2667203T3 (es) * 2000-07-03 2018-05-10 Bristol-Myers Squibb Company Usos de moléculas mutantes de CTL4 solubles
EP1368059A1 (fr) * 2001-01-26 2003-12-10 Emory University Procedes pour induire la tolerance de transplantations d'organe et corriger les hemoglobinopathies
DK1397153T3 (da) * 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler

Also Published As

Publication number Publication date
IS6667A (is) 2003-01-02
MY137552A (en) 2009-02-27
DE60135029D1 (de) 2008-09-04
ZA200210058B (en) 2005-02-23
SI21078A (sl) 2003-06-30
CA2413190A1 (fr) 2002-01-10
LT1935427T (lt) 2018-05-10
IL153593A0 (en) 2003-07-06
HK1058486A1 (en) 2004-05-21
NO20026264L (no) 2003-02-19
TR201807700T4 (tr) 2018-06-21
TWI322153B (en) 2010-03-21
SK17742002A3 (sk) 2004-11-03
EP2281568A3 (fr) 2013-04-24
ES2667203T3 (es) 2018-05-10
BG110611A (bg) 2010-05-31
HRP20030071A2 (en) 2005-02-28
KR20080075564A (ko) 2008-08-18
WO2002002638A3 (fr) 2003-10-30
SI1935427T1 (en) 2018-05-31
AU2001273174C1 (en) 2002-01-14
LT2003002A (en) 2003-07-25
IS2834B (is) 2013-05-15
BG66024B1 (bg) 2010-11-30
YU101102A (sh) 2006-01-16
EP1935427A2 (fr) 2008-06-25
SI1372696T1 (sl) 2008-12-31
EP1372696B1 (fr) 2008-07-23
CA2413190C (fr) 2009-04-07
CY1109786T1 (el) 2011-04-06
CY2008017I1 (el) 2009-11-04
HUP0301727A3 (en) 2008-08-28
WO2002002638A2 (fr) 2002-01-10
US20030083246A1 (en) 2003-05-01
KR20030017606A (ko) 2003-03-03
CN1477968A (zh) 2004-02-25
AU2001273174B2 (en) 2006-05-18
US7455835B2 (en) 2008-11-25
AU7317401A (en) 2002-01-14
HUS1000008I1 (hu) 2019-06-28
JP2004517806A (ja) 2004-06-17
NO20026264D0 (no) 2002-12-27
LV12993B (en) 2003-10-20
KR100895552B1 (ko) 2009-04-29
RU2287340C2 (ru) 2006-11-20
HUP0301727A2 (hu) 2003-09-29
NO20100580L (no) 2003-02-19
EE200300004A (et) 2004-10-15
PE20020772A1 (es) 2002-09-06
CA2630062A1 (fr) 2002-01-10
BG107362A (bg) 2003-09-30
IL153593A (en) 2009-09-01
KR20080025216A (ko) 2008-03-19
LT5063B (lt) 2003-11-25
ATE401909T1 (de) 2008-08-15
EP1935427A3 (fr) 2011-05-25
CY2008017I2 (el) 2016-08-31
EP1935427B1 (fr) 2018-03-07
AR035037A1 (es) 2004-04-14
KR100864120B1 (ko) 2008-10-16
UY26815A1 (es) 2002-01-31
PL207534B1 (pl) 2010-12-31
CN1318086C (zh) 2007-05-30
MXPA02012603A (es) 2003-05-14
CZ20024261A3 (cs) 2004-08-18
ES2310557T3 (es) 2009-01-16
BR0112104A (pt) 2004-07-20
HRP20030071B1 (hr) 2014-01-03
EP3384924A1 (fr) 2018-10-10
PL365942A1 (en) 2005-01-24
BG66454B1 (bg) 2014-10-31
EP1372696A2 (fr) 2004-01-02
AR066511A2 (es) 2009-08-26
TW200902546A (en) 2009-01-16
DK1935427T3 (en) 2018-06-06
HU226847B1 (en) 2009-12-28
HU227669B1 (en) 2011-11-28
RS50811B (sr) 2010-08-31
CZ303959B6 (cs) 2013-07-17
EP2281568A2 (fr) 2011-02-09
NO20100579L (no) 2003-02-19
PT1372696E (pt) 2008-10-24
DK1372696T3 (da) 2008-11-03
PL212205B1 (pl) 2012-08-31
EE05378B1 (et) 2011-02-15
CY1120577T1 (el) 2019-07-10
CA2630062C (fr) 2014-10-14
PT1935427T (pt) 2018-05-16
TWI311564B (en) 2009-07-01

Similar Documents

Publication Publication Date Title
CA2413190C (fr) Methodes de traitement de maladies rhumatismales a l'aide d'une molecule ctla4 soluble
KR100895134B1 (ko) 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
CA2447921C (fr) Procedes de protection d'une allogreffe de cellules secretrices d'insuline a l'aide de molecules mutantes ctla4 solubles
DK1868635T3 (en) METHODS OF TREATING IMMUNE DISEASES IN CONNECTION WITH ORGAN TRANSPLANTATION WITH SOLUBLE, Mutating CTLA4 MOLECULES
AU2001273174A1 (en) Methods for treating rheumatic diseases using a soluble CTLA4 molecule
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: ABATACEPT; REGISTRATION NO/DATE: EU/1/07/389/001 - EU/1/07/389/003 20070521

Spc suppl protection certif: 5019-2012

Filing date: 20120913

SPCY Application to extend an spc

Free format text: PRODUCT NAME: ABATACEPT; REGISTRATION NO/DATE: EU/1/07/389/001 - EU/1/07/389/003 20070523

Spc suppl protection certif: 5019-2012

Filing date: 20160620

SPCG Grant of an spc

Free format text: PRODUCT NAME: ABATACEPT; REGISTRATION NO/DATE: EU/1/07/389/001 - EU/1/07/389/003 20070523

Spc suppl protection certif: 274 5019-2012

Filing date: 20120913

Extension date: 20220523

SPCZ Extension of validity of an spc

Free format text: PRODUCT NAME: ABATACEPT; REGISTRATION NO/DATE: EU/1/07/389/001 - EU/1/07/389/003 20070523

Spc suppl protection certif: 274 5019-2012

Filing date: 20160620

Extension date: 20221123

MK4A Patent expired

Expiry date: 20210702